Targeting VCAM-1 with chimeric antigen receptor and regulatory T cell for abdominal aortic aneurysm treatment
Abstract Abdominal aortic aneurysm (AAA) is a life-threatening condition characterized by the dilation of the abdominal aorta, leading to a high risk of rupture. Current treatment options are limited, particularly for patients ineligible for surgical interventions. This study explores a novel immuno...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-08-01
|
| Series: | Communications Biology |
| Online Access: | https://doi.org/10.1038/s42003-025-08604-9 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Abstract Abdominal aortic aneurysm (AAA) is a life-threatening condition characterized by the dilation of the abdominal aorta, leading to a high risk of rupture. Current treatment options are limited, particularly for patients ineligible for surgical interventions. This study explores a novel immunotherapeutic approach using chimeric antigen receptor Treg cells targeting vascular cell adhesion molecule-1 (VCAM-1) to mitigate AAA progression. By leveraging the specificity and regulatory function of CAR-Treg cells, our research aims to modulate the immune response and reduce inflammation in the aneurysmal wall. Results from preclinical mouse models demonstrated that CAR-Treg cells effectively homed to the aneurysmal site, suppressed local inflammation, and decreased aortic dilation compared to control groups. These findings suggest that CAR-Treg cell therapy could provide a promising, non-surgical treatment option for AAA patients, addressing a critical unmet need in cardiovascular disease management. |
|---|---|
| ISSN: | 2399-3642 |